[go: up one dir, main page]

FI120501B - p53-proteiinin pitoisuuksia säätelevien kalpaiinin aktiivisuuden inhibiittorien käyttö syöpälääkkeiden valmistuksessa - Google Patents

p53-proteiinin pitoisuuksia säätelevien kalpaiinin aktiivisuuden inhibiittorien käyttö syöpälääkkeiden valmistuksessa Download PDF

Info

Publication number
FI120501B
FI120501B FI964783A FI964783A FI120501B FI 120501 B FI120501 B FI 120501B FI 964783 A FI964783 A FI 964783A FI 964783 A FI964783 A FI 964783A FI 120501 B FI120501 B FI 120501B
Authority
FI
Finland
Prior art keywords
lys
glu
protein
asp
ser
Prior art date
Application number
FI964783A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI964783A0 (fi
FI964783L (fi
Inventor
Jean-Marie Blanchard
Serge Carillo
Marc Peichaczyk
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of FI964783A0 publication Critical patent/FI964783A0/fi
Publication of FI964783L publication Critical patent/FI964783L/fi
Application granted granted Critical
Publication of FI120501B publication Critical patent/FI120501B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI964783A 1994-05-31 1996-11-29 p53-proteiinin pitoisuuksia säätelevien kalpaiinin aktiivisuuden inhibiittorien käyttö syöpälääkkeiden valmistuksessa FI120501B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9406583 1994-05-31
FR9406583A FR2720277B1 (fr) 1994-05-31 1994-05-31 Méthode de traitement des cancers par régulation de la protéine P53.
FR9500670 1995-05-22
PCT/FR1995/000670 WO1995033060A1 (fr) 1994-05-31 1995-05-22 Methode de traitement des cancers par regulation de la proteine p53

Publications (3)

Publication Number Publication Date
FI964783A0 FI964783A0 (fi) 1996-11-29
FI964783L FI964783L (fi) 1996-11-29
FI120501B true FI120501B (fi) 2009-11-13

Family

ID=9463670

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964783A FI120501B (fi) 1994-05-31 1996-11-29 p53-proteiinin pitoisuuksia säätelevien kalpaiinin aktiivisuuden inhibiittorien käyttö syöpälääkkeiden valmistuksessa

Country Status (8)

Country Link
EP (1) EP0763121A1 (fr)
JP (1) JPH10500978A (fr)
AU (1) AU714209B2 (fr)
CA (1) CA2190293C (fr)
FI (1) FI120501B (fr)
FR (1) FR2720277B1 (fr)
NO (1) NO321411B1 (fr)
WO (1) WO1995033060A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518488C1 (de) * 1995-05-19 1996-10-10 Progen Biotechnik Gmbh Autoantigen, geeignet zur Feststellung einer Thromboseneigung
EP0799892A3 (fr) * 1996-04-05 1998-08-12 Takeda Chemical Industries, Ltd. Calpain, sa préparation et son utilisation
US6232454B1 (en) 1998-02-27 2001-05-15 Incyte Genomics, Inc. Human proteinase molecules
AU2344100A (en) * 1998-11-18 2000-06-05 Canji, Inc. Viral vectors with late transgene expression
AU2001247922A1 (en) * 2000-03-31 2001-10-15 Parker Hughes Institute Calpain inhibitors in cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753665B2 (ja) * 1984-04-20 1995-06-07 財団法人癌研究会 抗転移剤
US5340922B1 (en) * 1988-05-31 1999-11-02 Mclean Hospital Corp Neural calcium-activated neutral proteinase inhibitors
EP0395309B1 (fr) * 1989-04-28 1995-12-27 Takara Shuzo Co. Ltd. Polypeptide semblable à la calpastatine humaine
JPH0641067A (ja) * 1992-04-20 1994-02-15 Kitasato Inst:The 新規カルパイン阻害物質ｋｐ−１２４１及びその製造法
EP0580161A1 (fr) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Traitement prophylactique et thérapeutique de la maladie d'Alzheimer
US5607831A (en) * 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death

Also Published As

Publication number Publication date
FI964783A0 (fi) 1996-11-29
FR2720277A1 (fr) 1995-12-01
EP0763121A1 (fr) 1997-03-19
CA2190293C (fr) 2011-06-28
AU714209B2 (en) 1999-12-23
WO1995033060A1 (fr) 1995-12-07
CA2190293A1 (fr) 1995-12-07
NO321411B1 (no) 2006-05-08
FI964783L (fi) 1996-11-29
JPH10500978A (ja) 1998-01-27
FR2720277B1 (fr) 1996-07-12
NO964772L (no) 1996-11-11
NO964772D0 (no) 1996-11-11
AU2620695A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
FI115771B (fi) Menetelmä apolipoproteiinin Al-Milano-dimeerin valmistamiseksi
CA2174556C (fr) Procedes et compositions relatifs a l'adenovirus p53 recombine
KR100330142B1 (ko) 재조합 바이러스 및 유전자 치료에서의 그의 사용
JP2655752B2 (ja) 組換えヒト第▲ｖｉｉｉ▼因子誘導体
TW494104B (en) Peptide having antithronbotic activity and process for producing the same
TW434260B (en) New variants of apolipoprotein A-I
AU710727B2 (en) Adenovirus comprising a gene coding for glutathion peroxidase
AU724324B2 (en) p16 expression constructs and their application in cancer therapy
JP2010526527A (ja) 抗腫瘍活性を有する新規なポリペプチド
JP3013896B2 (ja) ヒトマンガンスーパーオキシドジスムターゼを含む薬剤組成物
CA3121528A1 (fr) Anellosomes et methodes d'utilisation
JPH09509324A (ja) 増殖阻止ホメオボックス遺伝子
FI90353B (fi) Plasmidi humaani mangaanisuperoksididismutaasin ilmentämiseksi bakteereissa sekä menetelmä entsymaattisesti aktiivisen humaani mangaanisuperoksididismutaasin tuottamiseksi ja talteenottamiseksi
FI120501B (fi) p53-proteiinin pitoisuuksia säätelevien kalpaiinin aktiivisuuden inhibiittorien käyttö syöpälääkkeiden valmistuksessa
NZ269619A (en) Alpha-1-antichymotrypsin (serine protease inhibitor) and its use
EP2687537A1 (fr) Médicament contre la protéine x du virus de l'hépatite b utlisant un polypeptide
CN107073078A (zh) 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物
KR102566745B1 (ko) 암의 예방 또는 치료를 위한 Runx3 변이 단백질
US7837991B2 (en) Method of cancer treatment by p53 protein control
US20230220007A1 (en) Setd7 epigenetic modulators
JPH10203967A (ja) 単純ヘルペスウイルス１型プロテアーゼ阻害剤
WO1994014950A1 (fr) Dismutase de superoxyde de manganese humaine de type variant
MXPA96005522A (en) Method for the treatment of cancer through the control of protein
US5164315A (en) Basic protein phospholiphase A2
JPH03123490A (ja) 新規なセリンプロテアーゼインヒビター蛋白質、これを含む医薬、この蛋白質のためにコードするｄｎａ配列及びこれら蛋白質、医薬及びｄｎａ配列を作り出す方法

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: AVENTIS PHARMA S.A.

FG Patent granted

Ref document number: 120501

Country of ref document: FI

MM Patent lapsed